Synthesis and Characterization of the R27S Genetic Variant of Insulin-like Peptide 5.

ChemMedChem 2018 04 23;13(8):852-859. Epub 2018 Mar 23.

Novo Nordisk Research Center Indianapolis, 5225 Exploration Drive, Indianapolis, IN, 46241, USA.

We report the synthesis and in vitro bioactivity assessment for an insulin-like peptide 5 (INSL5) analogue that was recently discovered as a genetic mutation in an Amish population. The mutation was associated with improved metabolic status, and receptor-based antagonism was proposed as a potential mechanism for the altered phenotype. We determined the specific peptide analogue to be fully potent and of maximal efficacy at the human relaxin family peptide receptor 4 (RXFP4), suggesting an alternative basis for the observed effect. In preparation of this synthetically challenging hormone, we have introduced several improvements such as implementation of isoacyl chemistry for high-efficiency preparation of INSL5 B-chain and selective intramolecular A6-11 disulfide formation as a first step in sequential disulfide assembly.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.201800057DOI Listing
April 2018
7 Reads

Publication Analysis

Top Keywords

phenotype determined
4
chemistry high-efficiency
4
altered phenotype
4
high-efficiency preparation
4
determined specific
4
specific peptide
4
isoacyl chemistry
4
analogue fully
4
peptide analogue
4
mechanism altered
4
preparation insl5
4
status receptor-based
4
metabolic status
4
selective intramolecular
4
receptor-based antagonism
4
antagonism proposed
4
potential mechanism
4
proposed potential
4
insl5 b-chain
4
fully potent
4

References

(Supplied by CrossRef)

Bathgate et al.
Physiol. Rev. 2013

Shabanpoor et al.
Vitam. Horm. 2009

Luo et al.
Biochem. J. 2015

Burnicka-Turek et al.
Endocrinology 2012

Lee et al.
Mol. Metab. 2016

Grosse et al.
Proc. Natl. Acad. Sci. USA 2014

Liu et al.
J. Biol. Chem. 2005

Conklin et al.
Genomics 1999

Similar Publications